 |
3 Products |  |
11 Diseases | | 3 Products |
|
1 Trial |  |
288 News |  |
| 1234» |
- || batiraxcept (AVB-500) / Aravive, Imfinzi (durvalumab) / AstraZeneca
Trial completion, Trial completion date: AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Oct 28, 2024
P1/2, N=12, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Oct 2024
- | batiraxcept (AVB-500) / Aravive
Enrollment change, Trial withdrawal: AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer (clinicaltrials.gov) - Oct 1, 2024
P1, N=0, Withdrawn, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Oct 2024 N=36 --> 0 | Not yet recruiting --> Withdrawn
- | batiraxcept (AVB-500) / Aravive, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Combination therapy: AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Sep 5, 2024
P1/2, N=12, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=36 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Aug 2024 --> Aug 2025
- | batiraxcept (AVB-500) / Aravive, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy: AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jun 14, 2024
P1/2, N=12, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Aug 2024 --> Aug 2025 Trial completion date: Feb 2025 --> Aug 2024 | Trial primary completion date: Feb 2025 --> Aug 2024
- | batiraxcept (AVB-500) / Aravive
Trial completion date, Trial primary completion date, Combination therapy: AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer (clinicaltrials.gov) - Jun 12, 2024
P1, N=36, Not yet recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Feb 2025 --> Aug 2024 | Trial primary completion date: Feb 2025 --> Aug 2024 Trial completion date: Jan 2034 --> Jun 2034 | Trial primary completion date: Jan 2029 --> Jun 2029
- || batiraxcept (AVB-500) / Aravive, Imfinzi (durvalumab) / AstraZeneca
P1 data, Journal, Combination therapy: Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. (Pubmed Central) - May 10, 2024
P1/2
Batiraxcept effectively reduced serum GAS6 levels at 1-h post-treatment, resulting in trough levels below the limit of detection in all cases but one. In conclusion, the combination of batiraxcept and durvalumab was safe and tolerable but did not demonstrate anti-tumor activity in a heterogenous population of patients with recurrent PROC.
- batiraxcept (AVB-500) / Aravive
AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer. (E451) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1817;
P3
The addition of batiraxcept to paclitaxel did not improve PFS or OS. However, in AXL high tumors, the PFS and OS were higher in participants who received batiraxcept with paclitaxel compared to paclitaxel alone.
- || batiraxcept (AVB-500) / Aravive
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer (clinicaltrials.gov) - Jan 17, 2024
P1, N=36, Not yet recruiting, Sponsor: Washington University School of Medicine
However, in AXL high tumors, the PFS and OS were higher in participants who received batiraxcept with paclitaxel compared to paclitaxel alone. Trial completion date: Aug 2033 --> Nov 2033 | Initiation date: Dec 2023 --> Mar 2024 | Trial primary completion date: Aug 2028 --> Nov 2028
- | batiraxcept (AVB-500) / Aravive, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy: AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 27, 2023
P1/2, N=12, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Aug 2033 --> Nov 2033 | Initiation date: Dec 2023 --> Mar 2024 | Trial primary completion date: Aug 2028 --> Nov 2028 Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
- ||| batiraxcept (AVB-500) / Aravive, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Combination therapy: AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 26, 2023
P1/2, N=12, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025 N=19 --> 12
- || batiraxcept (AVB-500) / Aravive
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer (clinicaltrials.gov) - Oct 30, 2023
P1, N=36, Not yet recruiting, Sponsor: Washington University School of Medicine
N=19 --> 12 Trial completion date: Apr 2033 --> Aug 2033 | Initiation date: Sep 2023 --> Dec 2023 | Trial primary completion date: May 2028 --> Aug 2028
- ||||| batiraxcept (AVB-500) / Aravive
Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Monotherapy, Metastases: AVB500-RCC-003: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Oct 30, 2023
P1b/2, N=72, Terminated, Sponsor: Aravive, Inc.
Trial completion date: Apr 2033 --> Aug 2033 | Initiation date: Sep 2023 --> Dec 2023 | Trial primary completion date: May 2028 --> Aug 2028 Trial completion date: Mar 2025 --> Aug 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Aug 2023; Due to business reasons
- ||||||||| batiraxcept (AVB-500) / Aravive
Trial completion date, Trial termination, Combination therapy: ENGOT OV66: Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (clinicaltrials.gov) - Oct 30, 2023
P3, N=366, Terminated, Sponsor: Aravive, Inc.
There was no detriment to overall survival. No new safety signals were identified.
- | batiraxcept (AVB-500) / Aravive
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: AVB500-PC-005: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Oct 30, 2023
P1b/2, N=34, Terminated, Sponsor: Aravive, Inc.
No new safety signals were identified. N=99 --> 34 | Trial completion date: Oct 2025 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Oct 2024 --> Aug 2023; Due to business reasons
- | Bavencio (avelumab) / EMD Serono, batiraxcept (AVB-500) / Aravive
Trial primary completion date, Combination therapy, Metastases: COAXIN: Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (clinicaltrials.gov) - Oct 13, 2023
P1, N=19, Active, not recruiting, Sponsor: University of Oklahoma
N=99 --> 34 | Trial completion date: Oct 2025 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Oct 2024 --> Aug 2023; Due to business reasons Trial primary completion date: Aug 2023 --> Jan 2024
- | batiraxcept (AVB-500) / Aravive, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy: AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 18, 2023
P1/2, N=19, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Aug 2023 --> Jan 2024 Trial completion date: Sep 2023 --> Feb 2024 | Trial primary completion date: Sep 2023 --> Feb 2024
- batiraxcept (AVB-500) / Aravive, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy () - Jul 27, 2023 - Abstract #ESMO2023ESMO_3343;
P1b/2
Table: 1889P Conclusions BT + cabo demonstrated acceptable tolerability and promising efficacy in treatment-refractory ccRCC pts. BT + cabo will be further studied in a P3 trial of 2L+ ccRCC patients whose disease has progressed following IO and VEGF-TKI therapies.
- batiraxcept (AVB-500) / Aravive
Phase 1b/2 Study of Batiraxcept (AVB-S6-500, BT) plus Nab-paclitaxel (NP) and Gemcitabine (G) as first-line treatment (1L) for metastatic pancreatic adenocarcinoma (PDAC) () - Jul 27, 2023 - Abstract #ESMO2023ESMO_3154;
- ||||| batiraxcept (AVB-500) / Aravive, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, Combination therapy, Monotherapy, Metastases: Phase 2 Study of Batiraxcept (AVB-S6-500, an AXL inhibitor) as Monotherapy, in Combination With Cabozantinib (Cabo), and in Combination With Cabo and Nivolumab (Nivo) in Patients With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) @xingao04 #MGCCatASCO23 https://t.co/I4j2RKV3WG (Twitter) - Jun 3, 2023
- batiraxcept (AVB-500) / Aravive
Phase 1b study of batiraxcept (AVB-S6-500, BT) plus gemcitabine (G) and nab-paclitaxel (NP) as first-line treatment (1L) for advanced pancreatic adenocarcinoma (PDAC). () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5229;
P1b/2
Patients with BT trough > MEC had longer PFS and OS. In addition, in these patients OS appears longer than historical data of 8.5 months.
- batiraxcept (AVB-500) / Aravive, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC). (On Demand | Hall A; Poster Bd # 26) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2035;
P1b/2
Batiraxcept-based combinations demonstrated efficacy and tolerability. Given encouraging safety and efficacy signals, batiraxcept + cabo will be further studied in a phase 3 trial of 2L+ ccRCC patients whose disease has progressed on prior IO and VEGF-TKI treatment.
- || batiraxcept (AVB-500) / Aravive
New P1 trial, Combination therapy: AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer (clinicaltrials.gov) - Apr 24, 2023
P1, N=36, Not yet recruiting, Sponsor: Washington University School of Medicine
- | Bavencio (avelumab) / EMD Serono, batiraxcept (AVB-500) / Aravive
Trial primary completion date, Combination therapy, Metastases: COAXIN: Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (clinicaltrials.gov) - Apr 18, 2023
P1, N=19, Active, not recruiting, Sponsor: University of Oklahoma
Given encouraging safety and efficacy signals, batiraxcept + cabo will be further studied in a phase 3 trial of 2L+ ccRCC patients whose disease has progressed on prior IO and VEGF-TKI treatment. Trial primary completion date: Apr 2022 --> Jul 2023
- ||||| batiraxcept (AVB-500) / Aravive
Enrollment closed, Combination therapy: ENGOT OV66: Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (clinicaltrials.gov) - Mar 23, 2023
P3, N=350, Active, not recruiting, Sponsor: Aravive, Inc.
Trial primary completion date: Apr 2022 --> Jul 2023 Recruiting --> Active, not recruiting
- ||| batiraxcept (AVB-500) / Aravive
Trial completion, Combination therapy: AVB500-OC-002: Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer (clinicaltrials.gov) - Feb 13, 2023
P1b/2, N=53, Completed, Sponsor: Aravive, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || batiraxcept (AVB-500) / Aravive
Trial completion date, Trial primary completion date, Metastases: AVB500-PC-005: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Feb 10, 2023
P1b/2, N=99, Recruiting, Sponsor: Aravive, Inc.
Active, not recruiting --> Completed Trial completion date: Apr 2024 --> Oct 2025 | Trial primary completion date: Apr 2023 --> Oct 2024
- || batiraxcept (AVB-500) / Aravive
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: AVB500-RCC-003: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Jan 18, 2023
P1b/2, N=80, Active, not recruiting, Sponsor: Aravive, Inc.
Trial completion date: Apr 2024 --> Oct 2025 | Trial primary completion date: Apr 2023 --> Oct 2024 Recruiting --> Active, not recruiting | Trial completion date: Jul 2023 --> Mar 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
- batiraxcept (AVB-500) / Aravive, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC). (On Demand | Level 1, West Hall; Poster Board No. G17) - Jan 10, 2023 - Abstract #ASCOGU2023ASCO_GU_794;
P1b/2
No new safety signals were noted. Efficacy for the combination is encouraging compared to historical cabozantinib monotherapy data.
- | batiraxcept (AVB-500) / Aravive, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy: AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 9, 2022
P1/2, N=19, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Efficacy for the combination is encouraging compared to historical cabozantinib monotherapy data. Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
- | Bavencio (avelumab) / EMD Serono, batiraxcept (AVB-500) / Aravive
Trial completion date, Combination therapy, Metastases: COAXIN: Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (clinicaltrials.gov) - Nov 22, 2022
P1, N=19, Active, not recruiting, Sponsor: University of Oklahoma
Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Sep 2023 Trial completion date: Apr 2023 --> Sep 2024
- batiraxcept (AVB-500) / Aravive
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO/PACLITAXEL-CONTROLLED STUDY OF BATIRAXCEPT IN COMBINATION WITH WEEKLY PACLITAXEL IN PATIENTS WITH PLATINUMRESISTANT RECURRENT OVARIAN CANCER (GOG-3059/ENGOT OV-66) () - Sep 9, 2022 - Abstract #IGCS2022IGCS_1058;
P3
Longer PFS and OS times were observed in patients who had not been previously treated with bevacizumab (bev-naïve). Trial in progress: there are no available conclusions at the time of submission
- | batiraxcept (AVB-500) / Aravive
Journal: GAS6-AXL inhibition by AVB-500 overcomes resistance to paclitaxel in endometrial cancer by decreasing tumor cell glycolysis. (Pubmed Central) - Aug 6, 2022
Finally, multiple glycolytic metabolites were lower in the tumors treated with AVB-500 + paclitaxel than in tumors treated with paclitaxel alone. Our study provides strong pre-clinical rationale for combining AVB-500 with paclitaxel in aggressive endometrial cancer models.
- |||| batiraxcept (AVB-500) / Aravive
Why is there not more excitement for batiraxcept after impressive ASCO data... I am over the moon excited... would love my brother to get access to treat Metastatic NSCLC with ALK mutation, bc AXL is key to its spread. https://t.co/oEdYfRItvY (Twitter) - Jul 16, 2022
- ||||| Biomarker: #ASCO22 Poster discussions: 1) PhI LITESPARK-001 #HIF-2a inh belzutifan 41 mo F/U ORR 25% in pre-IO and VEGF-tx #ccRCC, 2) PhIb/II AXL recomb fusion protein batiraxcept + cabo 60 ORR 42% after >1L tx in adv #kcsm, 3) change in abx res genes predict benefit to CBM588 + nivo/ipi (Twitter) - Jun 4, 2022
- |||||| batiraxcept (AVB-500) / Aravive, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Biomarker, Combination therapy: Encouraging data showing promising activity of batiraxcept (targeting AXL) in combination with cabozantinib in mRCC - notably the sAXL/GAS6 Biomarker enriched response (67%). No additive toxicity.. #ASCO2022 (Twitter) - Jun 4, 2022
- ||||||| Bavencio (avelumab) / EMD Serono, Pfizer, batiraxcept (AVB-500) / Aravive
Clinical: 📍 Phase Ib study of avelumab and novel AXL inhibitor avb-S6-500 in patients with metastatic urothelial carcinoma (mUC) @ASCO #ASCO22 @AbhiTrip87 https://t.co/9oyHxYgeHn (Twitter) - Jun 3, 2022
- |||||| Bavencio (avelumab) / EMD Serono, Pfizer, batiraxcept (AVB-500) / Aravive
Clinical, P1 data: @ASCO #ASCO22 Abstract#4579. Preliminary results from phase 1B investigator initiated trial of avelumab+ batiraxcept (selective AXL inhibitor) in IO naive mUC. Concurrent Axl and PD-L1 inhibition had acceptable safety profile (DLT:1 patient); encouraging efficacy (ORR:36%) (Twitter) - May 30, 2022
- || Bavencio (avelumab) / EMD Serono, batiraxcept (AVB-500) / Aravive
Enrollment closed, Trial completion date, Combination therapy, Metastases: COAXIN: Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (clinicaltrials.gov) - May 5, 2022
P1, N=19, Active, not recruiting, Sponsor: University of Oklahoma
Our study provides strong pre-clinical rationale for combining AVB-500 with paclitaxel in aggressive endometrial cancer models. Recruiting --> Active, not recruiting | Trial completion date: Jul 2022 --> Apr 2023
- batiraxcept (AVB-500) / Aravive, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140). (Available On Demand; 89b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2529;
P1b/2
Exploratory objectives include pharmacokinetic and pharmacodynamic assessments. The Phase 2 portion of this Ph1b/2 study is currently enrolling.
- Bavencio (avelumab) / EMD Serono, Pfizer, batiraxcept (AVB-500) / Aravive
Phase Ib study of avelumab and novel AXL inhibitor avb-S6-500 in patients with metastatic urothelial carcinoma (mUC). (Available On Demand; 70) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2509;
P1
Albeit small sample size, the efficacy of the combination was encouraging and ORR compares favorably to that previously reported with PD-1/L1 inhibitor monotherapy. Updated safety, efficacy and biomarker data will be presented.
- batiraxcept (AVB-500) / Aravive, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140). (Available On Demand; 3) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2426;
P1b/2
The RP2D of batiraxcept was identified as 15 mg/kg. Early efficacy signals were observed including 100% DOR at 3 months.
- batiraxcept (AVB-500) / Aravive
GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis. () - Apr 9, 2022 - Abstract #SRI2022SRI_699;
Additionally, continued identifcation of viable biomarkers is critical to the success of targeted therapies such as AVB-500. Given AXL’s role in glucose homeostasis, one or more glycolytic intermediates may prove to be a useful biomarker to help predict sensitivity in patients, thus tailoring who would beneft from this treatment combination.
- batiraxcept (AVB-500) / Aravive, Herceptin (trastuzumab) / Roche
AVB-S6-500, a Receptor Tyrosine Kinase AXL Inhibitor, Improves the Therapeutic Efficacy of Trastuzumab in Uterine Serous Cancers. () - Apr 6, 2022 - Abstract #SRI2022SRI_492;
There was co-localization of AXL and HER2 receptors seen in both uterine serous cancer cell lines. Our data suggest that the addition of AVB-S6-500 increased the therapeutic efficacy of Trastuzumab therapy in uterine serous cancers.
- | paclitaxel / Generic mfg.
Journal, PARP Biomarker: GAS6/AXL inhibition enhances ovarian cancer sensitivity to chemotherapy and PARP inhibition through increased DNA damage and enhanced replication stress. (Pubmed Central) - Mar 31, 2022
Implications: GAS6/AXL is a novel target to sensitize ovarian cancers to carboplatin and olaparib. Additionally, GAS6 levels can be associated with response to carboplatin treatment.
- ||| batiraxcept (AVB-500) / Aravive
Honored to be awarded this at our annual mtg for the Ph 1b trial on AVB-500 + pac in platinum-resistant ovarian cancer. Thanks @AndreaHagemann for capturing. Feel fortunate to have so much support from such amazing colleagues and friends. #AXLerate-OC #GOG3059 @GOG #takesateam (Twitter) - Mar 21, 2022
- batiraxcept (AVB-500) / Aravive
Exposure-response analysis of batiraxcept and application to recommended phase 2 dose in platinum-resistant ovarian and clear cell renal cancers (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_6686;
P1, P1b/2,
Consistent with emerging U.S. Food and Drug Administration guidance around a more thoughtful approach to dose selection in cancer (“Project Optimus”), E‑R analysis supported the identification of batiraxcept 15mg/kg as the RP2D in the PROC P1b study. Furthermore, PK/PD and preliminary activity of batiraxcept 15mg/kg+cabozantinib are consistent with these data and support the batiraxcept RP2D of 15mg/kg across different tumor types and combinations with batiraxcept.
- batiraxcept (AVB-500) / Aravive
GAS6-AXL inhibition by AVB-500 overcomes resistance to paclitaxel in endometrial cancer by decreasing tumor cell glycolysis (Section 16) - Mar 9, 2022 - Abstract #AACR2022AACR_2394;
Additionally, continued identification of viable biomarkers is critical to the success of targeted therapies such as AVB-500. Given AXL’s role in glucose homeostasis, one or more glycolytic intermediates may prove to be a useful biomarker to help predict sensitivity in patients, thus tailoring who would benefit from this treatment combination.
- || batiraxcept (AVB-500) / Aravive
Trial completion: Phase 1 Study of 3D229 in Healthy Subjects (clinicaltrials.gov) - Mar 2, 2022
P1, N=24, Completed, Sponsor: 3D Medicines
Given AXL’s role in glucose homeostasis, one or more glycolytic intermediates may prove to be a useful biomarker to help predict sensitivity in patients, thus tailoring who would benefit from this treatment combination. Active, not recruiting --> Completed
- batiraxcept (AVB-500) / Aravive, Herceptin (trastuzumab) / Roche
AVB-S6-500, a receptor tyrosine kinase AXL inhibitor, improves the therapeutic efficacy of trastuzumab in uterine serous cancers (TBD) - Jan 26, 2022 - Abstract #SGO2022SGO_420;
Active, not recruiting --> Completed Learning Objective: Conclude that the combination of Trastuzumab and AVB500 lead to decrease uterine serous cancer cell proliferation and invasion in vitro and tumor burden in vivo in uterine serous cancer cell lines that express both AXL and HER2/neu receptors.
- batiraxcept (AVB-500) / Aravive
GOG-3059//ENGOT OV-66/AXLerate-OC: A Phase III, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (TBD) - Jan 26, 2022 - Abstract #SGO2022SGO_328;